Imfinzi is the first perioperative immunotherapy approved for resectable gastric/GEJ cancers, offering a new treatment ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. This time, a groundbreaking FDA approval makes the PD-L1 inhibitor the first immunotherapy ...

The approved regimen includes neoadjuvant (therapy before surgery) Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi ...

(RTTNews) - AstraZeneca (AZN), Friday announced positive Phase III results from its POTOMAC trial, showing that adding one year of treatment with Imfinzi; durvalumab to standard BCG therapy ...

AstraZeneca’s Imfinzi approved in US as first and only perioperative immunotherapy for patients with early gastric and GEJ cancers: Cambridge, UK Thursday, November 27, 2025, 09 ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...

Patients were treated with neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy. The trial ...

AstraZeneca’s (AZN) Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC, whose disease has not progressed ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that Imfinzi (durvalumab) has been approved in the European Union for the treatment of adult patients with resectable ...